Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)



Status:Recruiting
Conditions:Hematology, Benign Prostate Hyperplasia, Urology
Therapuetic Areas:Hematology, Nephrology / Urology
Healthy:No
Age Range:45 - Any
Updated:4/26/2018
Start Date:February 21, 2018
End Date:December 2018
Contact:Jiao Kuang
Email:jkuang@transitiontherapeutics.com
Phone:416-260-7770

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

This study will evaluate the safety and effectiveness of different doses of OPK-88004
compared to placebo on prostate size and related lower urinary tract symptoms (LUTS) in men
with benign prostatic hyperplasia (BPH).

This clinical trial is designed as a randomized, placebo-controlled, multi-center phase 2
trial to evaluate the efficacy and safety of OPK-88004 in men with benign prostatic
hyperplasia. Eligible subjects will be randomized into one of two OPK-88004 treatment groups
or a placebo group after a 4-week screening period. Subjects will have monthly visits over a
16- week treatment period and will be evaluated for the effect of OPK-88004 on prostate
volume and safety measures, as well as plasma levels of OPK-88004.

Inclusion Criteria:

- Male 45 yrs or older

- BPH diagnosis

- Lower urinary tract symptoms secondary to BPH

- Enlarged prostate

- Have not received prior treatment with 5-ARIs (finasteride, dutasteride)

Exclusion Criteria:

- Post void residual volume ≥200 mL

- Previous pelvic, urinary tract surgery or procedures (e.g. radical prostatectomy,
pelvic surgery for removal of malignancy, or bowel resection; radiotherapy, penile
implant surgery)

- Lower urinary tract malignancy, obstruction or trauma

- History or presence of prostatic carcinoma

- Current treatment with androgens, antiandrogens, estrogens, LHRH agonists/antagonists,
or anabolic steroids

- Current neurologic disease or condition associated with neurogenic bladder (e.g.
Parkinson's disease, multiple sclerosis)

- Current treatment with potent CYP3A4 inhibitors such as itraconazole or ritonavir
We found this trial at
15
sites
Garden City, New York 11530
2451
mi
from 91732
Garden City, NY
Click here to add this to my saved trials
1800 SW 1 ST #208
Miami, Florida 33135
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
7940 Floyd Curl Dr.
San Antonio, Texas 78229
210-949-0122
1182
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Anniston, Alabama 36207
1842
mi
from 91732
Anniston, AL
Click here to add this to my saved trials
Aventura, Florida 33180
2320
mi
from 91732
Aventura, FL
Click here to add this to my saved trials
Elkridge, Maryland
2296
mi
from 91732
Elkridge, MD
Click here to add this to my saved trials
1922
mi
from 91732
Knoxville, TN
Click here to add this to my saved trials
Lincoln, California 95648
380
mi
from 91732
Lincoln, CA
Click here to add this to my saved trials
2950 Magic View Drive
Meridian, Idaho 83642
664
mi
from 91732
Meridian, ID
Click here to add this to my saved trials
New York, New York 10016
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Sacramento, California
366
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
Shreveport, Louisiana 71106
1403
mi
from 91732
Shreveport, LA
Click here to add this to my saved trials
120 Medical Boulevard
Spring Hill, Florida 34609
2120
mi
from 91732
Spring Hill, FL
Click here to add this to my saved trials
Tampa, Florida 33607
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
12626 Riverside Drive
Valley Village, California 91607
23
mi
from 91732
Valley Village, CA
Click here to add this to my saved trials